TD Cowen analyst Marc Frahm has maintained their bullish stance on XLO stock, giving a Buy rating on March 11.
Marc Frahm has given his Buy rating due to a combination of factors including Xilio Therapeutics’ strategic pivot towards developing masked T-cell engagers (TCEs) and its promising preclinical focus. The company has outlined plans to nominate development candidates for PSMA, CLDN18.2, and STEAP1 targets in the upcoming years, which indicates a strong pipeline and potential for future growth. Additionally, Xilio’s collaboration with AbbVie further strengthens its position in the biotech industry, providing a significant endorsement of its innovative approach.
Furthermore, the initial Phase II data for Xilio’s vilastobart combined with atezolizumab in MSS-CRC patients has shown competitive anti-tumor activity with an objective response rate (ORR) that surpasses existing salvage therapies. The combination also demonstrates a favorable safety and tolerability profile compared to other treatments, which enhances its appeal. The anticipated update in mid-2025, including additional patient data, could further validate the efficacy of this combination and attract potential partnerships to support broader clinical development.
In another report released on March 11, Morgan Stanley also maintained a Buy rating on the stock with a $5.00 price target.